knowledge -WSS

knowledge

author：comprehensive 2025-09-27 22:46:53 - browse：83576

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Judge rejects Trump's request to move Stormy Daniels hush

WSS

Tesla recalling nearly 16,000 of its 2021

Some top drug companies are starting to take action on climate

Why Congress must ban federal programs from using QALYs

7 more heat

CDC picks Alphabet's Verily for wasterwater surveillance contract

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Jerome Adams on the need for new antivirals for Covid

The United States is paying nearly triple for new Covid vaccines

BioMarin wins approval for gene therapy to treat hemophilia A

Divers poised to search for children washed away in Pennsylvania flash flood

New air purifier tech could be key to improving indoor air quality

What will Novo Nordisk's VC do with its influx of cash?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Malaria cases in Florida and Texas: Here’s what you need to know

With Roe v Wade overturned, abortion providers work to adapt

focus

Driven by the pandemic, applicants flood public health schools

Judge rejects Trump's request to move Stormy Daniels hush

What we owe ALS patients — and why one company fell short

Awakening the world to the whoosh: A patient's crusade

The stability of $0 premiums in Medicare Advantage

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

leisure time

hotspot

entertainment

hotspot